Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03189485 · ClinicalTrials.gov registry record
Tau PET Imaging in the NACC Study Cohort
A clinical trial of MCI and Normal Controls, sponsored by University of Pennsylvania.
- Active
- Registry status
- 106
- Enrollment target
- 1
- Study location
NCT03189485: Active study of MCI and Normal Controls, sponsored by University of Pennsylvania.
NCT03189485 is a study of MCI and Normal Controls that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 106 participants, below the 887-participant average among 5 other MCI trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03189485, a study of MCI and Normal Controls, is active but no longer recruiting, sponsored by University of Pennsylvania.
- ACTIVE NOT RECRUITING
- Registry status
- 106 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to measure the amount of a protein in the brain known as tau using an imaging procedure called Positron Emission Tomography (PET/CT). 18F-AV-1451 is a specialized radioactive PET imaging agent that is able to detect the presence of tau in the brain. In this study, the investigator will use the 18F-AV-1451 to capture images of tau in the brain. Findings from this study will likely provide insight into the mechanisms and distinctions of age-related cognitive decline and that of very early Alzheimer's disease.
Primary Outcome
Specific analyses will include quantitative measures of 18F-AV-1451 within the medial temporal lobe (MTL) and its relationship to volume and thickness of MTL subregions measured with high-resolution MRI.
Conditions Studied
Interventions
- DRUG the radiotracer 18F-AV-1451
Study Locations (1)
Pennsylvania
- UPenn - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2017-11-22 |
| Est. Completion | 2026-05-31 |
What the registry record for NCT03189485 still lists
NCT03189485 is an observational study that tracks outcomes without assigning an intervention. The registered 106 participants enrollment target is mid-sized for trials with a published cap, below the 887-participant average among 5 other MCI trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with MCI appearing as the primary indexed condition, and to 1 intervention - of which the radiotracer 18F-AV-1451 is the first listed.
NCT03189485 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03189485 about?
NCT03189485 is a clinical study titled "Tau PET Imaging in the NACC Study Cohort". The purpose of this study is to measure the amount of a protein in the brain known as tau using an imaging procedure called Positron Emission Tomography (PET/CT). 18F-AV-1451 is a specialized radioactive PET imaging agent that is able to detect the presence of tau in the brain. In this study, the in...
What is the current status of trial NCT03189485?
This trial is currently active not recruiting. The enrollment target is 106 participants. The study started on 2017-11-22. Estimated completion is 2026-05-31.
What conditions does trial NCT03189485 study?
This clinical trial studies the following conditions: MCI, Normal Controls.
What interventions are being tested in trial NCT03189485?
The interventions under investigation include: the radiotracer 18F-AV-1451 (DRUG).
Who is sponsoring clinical trial NCT03189485?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03189485 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for MCI
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Studying the Effects of Digital Interventions on Cognition, Wellbeing, Stress, and Sleep in Older Adults
RECRUITING · NA
-
Enhancing Attention and Wellbeing Using Digital Therapeutics
RECRUITING · NA
-
Exploring the Utility of [18F]3F4AP for Demyelination Imaging
RECRUITING · Phase 1
-
Neuromodulation of Memory in Aging
RECRUITING · NA
-
Accelerating Cognitive Gains From Digital Inverventions With Noninvasive Brain Stimulation
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03181048 · 106 participants · NA
Clinical Trial of Concomitant Hip Arthroscopy During PAO
- NCT04682158 · 106 participants · Phase 2
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
- NCT04724018 · 106 participants · Phase 1
Sacituzumab Govitecan Plus EV in Metastatic UC
- NCT04798274 · 106 participants · NA
Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI